Cargando…
Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis in a Patient Presenting with Acute Pancreatitis
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are a class of medications used for glycemic control in type II diabetes mellitus. Their mechanism of action involves preventing resorption of glucose at the proximal kidney, thereby promoting glucosuria and weight loss. However, they have also been...
Autores principales: | Badwal, Karun, Tariq, Tooba, Peirce, Diane |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6106964/ https://www.ncbi.nlm.nih.gov/pubmed/30159178 http://dx.doi.org/10.1155/2018/6450563 |
Ejemplares similares
-
Dapagliflozin-induced Late-onset Euglycemic Diabetic Ketoacidosis
por: Iqbal, Iqra, et al.
Publicado: (2019) -
Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin
por: Pujara, Shreya, et al.
Publicado: (2017) -
Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin in a Patient with Colon Malignancy
por: Papadokostaki, Eleni, et al.
Publicado: (2019) -
Dapagliflozin-Associated Euglycemic Diabetic Ketoacidosis Presenting With Severe Abdominal Pain Mimicking Acute Peritonitis
por: Wang, Qianwen, et al.
Publicado: (2022) -
Euglycemic Diabetic Ketoacidosis, a Misleading Presentation of Diabetic Ketoacidosis
por: Thawabi, Mohammad, et al.
Publicado: (2015)